GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Allied Biotech 1780.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

23.80

+0.21%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 849.5m

FY2016FY2025

Net income

TWD 129.5m

FY2016FY2025

Free cash flow

TWD 183.5m

FY2016FY2025

Shareholders' equity

TWD 1.23bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 849.5mTWD 806.9mTWD 720.4mTWD 716.7mTWD 676.8mTWD 618.1mTWD 639.4mTWD 765.3mTWD 681.7mTWD 573.6m
Gross profitTWD 308.6mTWD 258.4mTWD 246.4mTWD 271.0mTWD 258.1mTWD 241.2m—TWD 301.3mTWD 232.4mTWD 219.3m
Research and developmentTWD 28.4mTWD 26.1mTWD 26.1mTWD 24.6mTWD 25.7mTWD 24.6mTWD 24.3mTWD 25.0mTWD 28.4mTWD 22.7m
Operating incomeTWD 120.4mTWD 88.1mTWD 88.7mTWD 198.8mTWD 28.8mTWD 102.6mTWD 136.5mTWD 145.4mTWD 89.9mTWD 63.7m
Net incomeTWD 129.5mTWD 100.9mTWD 97.4mTWD 146.7mTWD 13.0mTWD 79.5mTWD 106.9mTWD 133.5mTWD 71.0mTWD 40.2m
Diluted earnings per share1.351.051.011.530.140.831.121.400.750.43

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 2.09bnTWD 2.26bnTWD 2.08bnTWD 2.18bnTWD 2.44bnTWD 2.26bnTWD 1.95bn———
Cash and short-term investments—TWD 987.2mTWD 724.8mTWD 793.0mTWD 1.14bnTWD 965.8mTWD 759.9m———
Total liabilitiesTWD 857.2mTWD 1.06bnTWD 910.1mTWD 999.4mTWD 1.36bnTWD 1.12bnTWD 791.1m———
DebtTWD 34.5mTWD 955.4mTWD 796.6mTWD 838.0mTWD 1.25bnTWD 1.00bnTWD 687.6m———
Shareholders' equityTWD 1.23bnTWD 1.20bnTWD 1.17bnTWD 1.18bnTWD 1.08bnTWD 1.15bnTWD 1.16bn———
Shares outstanding96m97m96m96m95m95m95m95m95m95m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsTWD 217.1mTWD 223.8mTWD 137.6mTWD 164.3mTWD 72.4mTWD 59.5m—TWD 159.6mTWD 100.4mTWD 127.3m
Capital spending−TWD 33.6m−TWD 26.8m−TWD 47.9m−TWD 54.7m−TWD 50.0m−TWD 56.8m—−TWD 43.7m−TWD 53.8m−TWD 21.4m
Free cash flowTWD 183.5mTWD 197.0mTWD 89.7mTWD 109.6mTWD 22.4mTWD 2.7m—TWD 115.9mTWD 46.6mTWD 106.0m
Dividends paid−TWD 96.0m−TWD 81.4m−TWD 114.5m−TWD 47.7m−TWD 76.1m−TWD 94.9m—−TWD 62.4m−TWD 42.6m−TWD 37.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 258.1mTWD 240.3mTWD 213.9mTWD 210.2mTWD 431.4mTWD 209.7mTWD 379.0mTWD 192.8m
Gross profitTWD 111.8mTWD 88.2mTWD 79.8mTWD 76.3mTWD 145.6mTWD 79.7mTWD 128.6mTWD 59.5m
Operating incomeTWD 45.1mTWD 40.3mTWD 20.3mTWD 28.9mTWD 69.0mTWD 36.7mTWD 40.8mTWD 16.0m
Net incomeTWD 28.8mTWD 38.5mTWD 48.7mTWD 64.5m−TWD 89.1mTWD 60.8mTWD 32.5mTWD 18.6m
Diluted earnings per share0.300.400.510.67-0.930.630.340.19
Cash from operationsTWD 51.0mTWD 65.0mTWD 85.0mTWD 59.0m−TWD 25.0mTWD 98.0mTWD 73.0mTWD 36.0m
Capital spending−TWD 8.0m−TWD 11.0m−TWD 10.0m−TWD 7.0m−TWD 10.0m−TWD 5.0m−TWD 15.0m−TWD 7.0m
Free cash flowTWD 43.0mTWD 54.0mTWD 75.0mTWD 52.0m−TWD 35.0mTWD 93.0mTWD 58.0mTWD 29.0m
Total assetsTWD 2.56bnTWD 2.18bnTWD 2.09bnTWD 2.30bnTWD 2.31bnTWD 2.33bnTWD 2.26bn—
Cash and short-term investments————TWD 1.08bn—TWD 987.2m—
DebtTWD 25.3mTWD 29.9mTWD 34.5mTWD 39.0mTWD 984.9mTWD 48.2mTWD 947.6m—
Shareholders' equityTWD 1.52bnTWD 1.27bnTWD 1.23bnTWD 1.19bnTWD 1.12bnTWD 1.26bnTWD 1.20bn—

Financial ratios

Data as of 28 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin36.3%32.0%34.2%37.8%38.1%39.0%
Operating margin21.4%17.8%18.8%27.7%4.3%19.1%
Net margin15.2%12.5%13.5%20.5%1.9%12.9%
Return on equity10.5%8.4%8.3%12.4%1.2%6.9%
Return on assets6.2%4.5%4.7%6.7%0.5%3.5%
Free cash flow yield10.9%10.8%8.0%9.5%5.3%5.1%
Revenue growth5.3%12.0%0.5%5.9%9.5%-3.3%
Earnings growth28.3%3.6%-33.6%1025.1%-83.6%-25.7%
Current ratio1.90x1.67x1.76x1.72x1.33x1.63x
Debt to equity0.03x0.79x0.68x0.70x1.15x0.76x
Equity ratio59.0%53.0%56.2%54.2%44.3%50.7%
Interest coverage10.47x10.32x10.45x16.92x2.56x13.09x
R&D as a share of sales3.3%3.2%3.6%3.4%3.8%4.0%
Buybacks as a share of market value0.3%-0.4%-0.1%-0.7%0.1%-0.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.8%6.6%4.9%
Operating income-15.4%3.3%8.9%
Net income-4.1%10.3%10.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin34.2%35.1%36.1%—
Operating margin12.6%16.0%14.3%14.7%
Net margin13.9%15.3%12.9%12.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings17.216.616.19.2111.520.215.611.621.643.5
Price to sales2.62.12.21.92.12.62.62.02.33.0

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 17 Jul 2025.

FY2025FY2024FY2023FY2022
Paid in the year1.000.851.200.50

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.